Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo
M. Larsabal(Hôpital Saint-André), Julien Sénéschal(Hôpital Saint-André), Katia Boniface(Université de Bordeaux), C. Jacquemin(Centre National de la Recherche Scientifique), Jérôme Rambert(Université de Bordeaux), Alain Taı̈eb(Université de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Denis Thiolat(Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers), S. Prey(Université de Bordeaux), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), A. Marti(Hôpital Saint-André)
Cited by 157
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k